Onsite Clinical Solutions LLC

1. Eli Lilly and Company $1,715,694 63 payments
2. AbbVie, Inc. $603,109 154 payments
3. GlaxoSmithKline, LLC. $577,068 166 payments
4. Pfizer Inc. $400,192 63 payments
5. Novartis Pharmaceuticals Corporation $158,940 1 payment
6. H. Lundbeck A S $133,659 64 payments
7. Amgen Inc. $86,472 7 payments
8. Sanofi US Services Inc. $60,499 9 payments
9. Braintree Laboratories, Inc. $51,868 8 payments
10. Kyowa Kirin Pharmaceutical Development, Inc $49,735 25 payments

1. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $1,208,311 7 payments
2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr $330,952 81 payments
3. Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $201,273 16 payments
4. Study name not reported $191,666 67 payments
5. M16-100 $181,832 52 payments
6. 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S $158,940 1 payment
7. 24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy $132,342 19 payments
8. An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $119,881 28 payments
9. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $99,280 43 payments
10. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $95,224 4 payments

1. Patient care $31,203 18 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.